MedTrace Logo

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 877

Last updated 2026-04-06

No results posted yet for this study

Summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin icodec

Insulin icodec will be administered as subcutaneous injection

DRUG

Insulin glargine

Insulin glargine will be administered as subcutaneous injection.

DRUG

Insulin aspart

Insulin aspart will be administered as a subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2027-01-25
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Poland
  • Puerto Rico
  • Romania
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076199 on ClinicalTrials.gov